Other
Valeant: We'll bump Allergan offer to $200 a share
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.
Oct 27, 2014
0
0